Search Results

Three-Month Data Published on VenaSeal Closure System for Incompetent GSVs

April 1, 2015—Nick Morrison, MD, et al reported early results of the randomized VeCLOSE pivotal trial of cyanoacrylate embolization (CAE) with the VenaSeal closure system (Medtronic) versus radiofrequency ablation (RFA) for the treatment of symptomatic incompetent great saphenous veins (GSVs) in the Journal of Vascular Surgery (2015;61:985–994).

Five-Year Outcomes Support Medtronic's VenaSeal Closure System in Patients With Chronic Venous Disease

April 17, 2019—The 5-year outcomes from the VeClose Extension study were presented by Nick Morrison, MD, at the Charing Cross Symposium, held April 15–18 in London, United Kingdom.

Medtronic Reports 12-Month VeClose Pivotal Trial Data for the VenaSeal Closure System

July 2, 2015—Medtronic plc announced that the 12-month results of the VeClose pivotal study demonstrated the safety and effectiveness of the VenaSeal closure system for the treatment of incompetent greater saphenous veins with a 96.8% closure rate. National Principal Investigator, Nick Morrison, MD, presented the data at the European Venous Forum 2015 in St.

Medtronic's VenaSeal Closure System Gains FDA Approval

February 20, 2015—The US Food and Drug Administration has announced the approval of Medtronic plc’s VenaSeal Closure System for the treatment of symptomatic lower extremity varicose veins through endovascular embolization with coaptation.

Medtronic Launches the VenaSeal Closure System to Treat Venous Reflux in United States

November 9, 2015—Medtronic plc announced the launch of the VenaSeal closure system in the United States.

VeClose Study Demonstrates Safety, Effectiveness of Covidien's VenaSeal Closure System

November 13, 2014—Covidien announced that the 6-month results of the VeClose pivotal study demonstrated the safety and effectiveness of the VenaSeal closure system in patients with chronic venous insufficiency having symptomatic reflux in the great saphenous vein.

American College of Phlebology to Present at MEDCAC Meeting on Venous Disease

July 1, 2016—The American College of Phlebology (ACP) recently announced that as part of a coalition of organizations dedicated to evidence-based care of venous disease, ACP has submitted a joint presentation to the Centers for Medicare & Medicaid Services (CMS) Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting on treatment strategies for patients with lower extremity chronic venous disease.  Additionally, the United States Compression Alliance (USCA) was invited to present information to the panel of medical professionals addressing the five published questions from CMS on lower extremity chronic venous disease.

Medtronic's VenaSeal Closure System Evaluated in Patients With Venous Reflux Disease

April 28, 2016—Medtronic plc announced new clinical data for the VenaSeal closure system demonstrating consistent long-term durability and improved quality of life in patients with venous reflux disease.